It was a pleasure to interview Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss treatment options for the management of amyotrophic lateral sclerosis (ALS).
The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- Could you give us a brief overview of the current status of disease-modifying therapies for ALS? (0:06)
- Why are there so few treatment options for the management of ALS? (1:26)
- What is AMX0035 and what is its mechanism of action? (2:37)
Disclosures: Sabrina Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma, Biohaven, Clene, Prilenia, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association; and reports personal consulting fees for advisory panels from Orion.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
